Status:
COMPLETED
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
Eligibility Criteria
Inclusion
- Clinical diagnosis of ankylosing spondylitis
- Active ankylosing spondylitis
Exclusion
- Complete ankylosis of spine
- Previous treatment with etanercept
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
566 Patients enrolled
Trial Details
Trial ID
NCT00247962
Start Date
December 1 2005
End Date
February 1 2008
Last Update
November 8 2012
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Heidelberg West, Victoria, Australia, 3081
2
Shenton Park, Western Australia, Australia, 6000
3
Innsbruck, Austria, 6020
4
Klagenfurt, Austria, A-9020